CME Learning Center

Genitourinary Cancer

Peer-to-Peer Clinical Connections: Sequencing Radioligand Therapies in Metastatic Castration-Resistant Prostate Cancer CME / ABIM MOC Did you know that radiopharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC) care have the potential to prolong survival and optimize the quality of life?
Medscape Education Oncology, March 2023
Medscape Onsite: Prostate and Bladder Cancer Updates From the Annual American Genitourinary Meeting CME / ABIM MOC Get the latest data on prostate and bladder cancer from the 2023 winter meetings.
Medscape Education Oncology, March 2023
Depicting LAG3: Exploring a New Target in Metastatic Melanoma CME / ABIM MOC Do you know the role of lymphocytic activation gene 3 (LAG3) in metastatic melanoma and its potential as a treatment target?
Medscape Education Oncology, March 2023
What's Your Take? Perspectives on Immunotherapy for Early-Stage Solid Tumors CME / ABIM MOC Did you know? Immunotherapy is now being used for the neoadjuvant and adjuvant treatment of solid tumors -- find out more here!
Medscape Education Oncology, February 2023
Advances in Urine-Based Prostate Screening: Simplifying Screening in Primary Care With Novel Tests CME / ABIM MOC Did you know that screening for prostate cancer remains controversial? Listen to Dr Neal Shore discuss the latest on screening for prostate cancer.
Medscape Education Family Medicine, December 2022
Advances in Urine-Based Prostate Cancer Screening: Expanding Access to Quality Care CME / ABIM MOC Did you know that recent advances in diagnostics are expanding access to non-invasive approaches to screening for prostate cancer?
Medscape Education Family Medicine, December 2022
Overcoming Barriers to Bladder Cancer Care CME / ABIM MOC Are you aware of the most common presenting sign or symptom observed in patients with bladder cancer?
Medscape Education Oncology, December 2022
Case Review: Team-Based Approaches to Optimize Androgen Deprivation Therapy in Advanced Prostate Cancer CME / ABIM MOC / CE Do you know which class of agents used for androgen deprivation therapy (ADT) appears to have the most cardiovascular risk?
Medscape Education Oncology, November 2022
Treatment Approaches in Early-Stage Bladder Cancer CME / ABIM MOC Did you know that bladder cancer is highly treatable in the localized stages? Learn more about the latest in treating early-stage bladder cancer.
Medscape Education Oncology, November 2022
Antibody-Drug Conjugates 101: A Multidisciplinary Perspective of ADC Use in Solid Tumors CE Thinking about using antibody-drug conjugates (ADCs) in patients with solid tumors? Join this discussion with our experts for strategies and perspectives.
Medscape Education Oncology, October 2022
Metastatic Castration-Resistant Prostate Cancer: Updates From the 2022 European Annual Meeting CME / ABIM MOC Are you up-to-date on the latest data in metastatic castration-resistant prostate cancer (mCRPC) from the 2022 European Society of Medical Oncology Congress?
Medscape Education Oncology, October 2022
Pathology State of Affairs: Underscoring the Value of Biomarker Testing for Solid Tumors  CME / ABIM MOC Are you up to date with current best practices for biomarker testing in solid malignancies? Find out more here!
Medscape Education Pathology, September 2022
Treatment Intensification With Nonhormonal Strategies CME / ABIM MOC Did you know that treatment intensification has been shown to improve outcomes for patients with hormone-sensitive prostate cancer (HSPC)?
Medscape Education Oncology, September 2022
Understanding and Overcoming Resistance to Anti-PD-1 Immunotherapy in Melanoma CME / ABIM MOC Dr Davies hosts Dr Luke in a podcast focused on understanding and overcoming resistance to anti-programmed cell death protein 1 (PD-1) immunotherapy.
Medscape Education Oncology, August 2022
Treatment Intensification With Androgen Deprivation Therapy and Novel Hormonal Therapies CME / ABIM MOC Are you up-to-date on all the treatment intensification options for your patients with metastatic hormone-sensitive prostate cancer (HSPC)?
Medscape Education Oncology, August 2022
PARP Inhibitor Combination Regimens for Prostate Cancer Management CME Do you know how PARP inhibitors exploit synthetic lethality to treat cancer?
Medscape Education Oncology, August 2022
Conceptual Overview of Treatment Intensification in Hormone-Sensitive Prostate Cancer CME / ABIM MOC What is treatment intensification for patients with hormone-sensitive prostate cancer (HSPC)?
Medscape Education Oncology, August 2022
Optimizing Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer CME / ABIM MOC / CE Do you know the data on androgen deprivation therapy, chemotherapy, and second-generation antiandrogens for hormone-sensitive prostate cancer (mHSPC)?
Medscape Education Oncology, July 2022
The State of the Therapeutics in Genitourinary Cancers: Where Are We Moving the Needle? CME / ABIM MOC Are you employing the latest therapies for your patients with genitourinary cancers?
Medscape Education Oncology, June 2022
A Genitourinary Overview of Bladder and Prostate Cancers CE Our nurse expert summarizes the latest in bladder and prostate cancer management.
Medscape Education Nurses, June 2022

What Are the Risks to Spouses of Patients With Cancer? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, March 3, 2023
National Cohort Study: What Is the Cancer Risk in Patients With Diverticular Disease? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, December 9, 2022
Do Nutrition and Physical Activity Affect Cancer Risk for Minority Women? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, November 4, 2022
Does Androgen Deprivation Therapy Increase Cardiovascular Risk? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, July 15, 2022
Can Leisure Time Physical Activity Reduce Obesity-Related Cancers? CME / ABIM MOC / CE
Medscape Education Clinical Briefs, May 27, 2022

CME Learning Center

Genitourinary Cancer

Latest Clinical Briefs

Further Reading